HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- (2- methyl- 4,5- bis(methylsulfonyl)benzoyl)guanidine

inhibits sodium hydrogen exchanger NHE-1; structure in first source

Also Known As:

EMD 87580; EMD-87580; EMD87580; N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine hydrochloride

Networked: 13 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Sulfones: 534
    - N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine: 13
- Amidines: 14
  - Guanidines: 29
    - N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine: 13

Experts

1.	Beier, Norbert: 4 articles (11/2015 - 01/2004)
2.	Al-Khoury, Johny: 3 articles (01/2022 - 04/2005)
3.	Bkaily, Ghassan: 3 articles (01/2022 - 04/2005)
4.	Jacques, Danielle: 3 articles (01/2022 - 04/2005)
5.	Scholz, Wolfgang: 3 articles (11/2015 - 01/2004)
6.	Karmazyn, Morris: 3 articles (01/2011 - 12/2003)
7.	Fliegel, Larry: 2 articles (10/2016 - 12/2003)
8.	Chahine, Mirna: 2 articles (11/2015 - 04/2005)
9.	Gan, Xiaohong Tracey: 2 articles (01/2004 - 12/2003)
10.	Kingma, J G: 1 article (01/2018)

Related Diseases

1.	Ischemia 01/01/2018 - "EMD 87580 given before ischemia or before reperfusion did not reduce infarct size (compared to vehicle-treated group). " 01/01/2018 - "The current study compared the efficacy of NHE1 blockade by N-[2-methyl-4,5-bis(methylsulfonyl)-benzoyl]-guanidine (EMD 87580 5 mg/kg) combined with first- or second-window IC on ischemic tolerance in dogs subject to 90-minute acute ischemia and 180-minute reperfusion. "
2.	Necrosis 01/01/2018 - "Significant protection against tissue necrosis was obtained by both first- and second-window IC, but additive cardioprotection (ie, greater than that afforded by IC) was not observed by treatment with EMD 87580. " 04/01/2005 - "Treatment of 30-day-old CMHs during the development of necrosis and in the absence of hypertrophy with the specific NHE-1 inhibitor EMD87580 (EMD) for 50 days significantly prevented the increase of NHE-1 protein level and intracellular Na(+) and Ca(2+) overloads as well as necrosis. " 11/01/2015 - "Using the UM-X7.1 hereditary cardiomyopathic and muscular dystrophy hamsters (HCMH), we tested the effects of lifelong preventive or curative treatments during the heart failure phase with the NHE-1 inhibitor EMD 87580 (EMD) or with the angiotensin-converting enzyme inhibitor cilazapril on the intracellular Na(+) and Ca(2+) overloads, elevated level of NHE-1, necrosis, hypertrophy, heart failure, and early death. "
3.	Reperfusion Injury 01/01/2018 - "These data demonstrate that EMD 87580 did not protect against ischemia-reperfusion injury regardless of the time of drug administration. " 01/01/2018 - "Inhibition of Na+/H+ Exchanger With EMD 87580 does not Confer Greater Cardioprotection Beyond Preconditioning on Ischemia-Reperfusion Injury in Normal Dogs." 08/15/2014 - "Cardioprotective efficacy against reperfusion injury of EMD-87580: Comparison to ischemic postconditioning."
4.	Hypertrophy 01/01/2011 - "The NHE-1-specific inhibitor EMD-87580 (EMD) attenuated changes in the expression of MFF proteins in both the models of hypertrophy. " 04/01/2005 - "Treatment of 30-day-old CMHs during the development of necrosis and in the absence of hypertrophy with the specific NHE-1 inhibitor EMD87580 (EMD) for 50 days significantly prevented the increase of NHE-1 protein level and intracellular Na(+) and Ca(2+) overloads as well as necrosis. " 12/01/2003 - "Both hypertrophy and elevated Na+ levels were prevented by the NHE-1-specific inhibitor EMD87580 as well as the aldosterone antagonist spironolactone, although the increased NHE-1 levels were prevented only by spironolactone. " 06/01/2015 - "Ang II-induced hypertrophy and OPN protein expression were regressed in the presence of an NHE1 inhibitor, EMD 87580, or a calcineurin inhibitor, FK506. "
5.	Infarction (Infarctions) 11/01/2003 - "We tested the hypothesis that increasing doses of NHE1 inhibitor EMD 87580 ((2-methyl-4,5-di-(methylsulfonyl)-benzoyl)-guanidine) delivered in blood cardioplegia (BCP) and by parenteral route at reperfusion reduce myocardial injury after surgical reperfusion of evolving infarction. " 01/01/2018 - "EMD 87580 given before ischemia or before reperfusion did not reduce infarct size (compared to vehicle-treated group). "

Related Drugs and Biologics

1.	Guanidine (Guanidine Nitrate)
2.	Proteins (Proteins, Gene)
3.	Calcineurin Inhibitors
4.	Sodium-Hydrogen Exchangers
5.	Cilazapril
6.	Paclitaxel (Taxol)
7.	Tacrolimus (Prograf)
8.	Spironolactone (Aldactone)
9.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
10.	Mineralocorticoid Receptor Antagonists

Related Therapies and Procedures

1.	Ischemic Postconditioning
2.	Induced Heart Arrest (Cardioplegia)
3.	Drug Therapy (Chemotherapy)
4.	Treatment Delay